Mega Genomics Limited announced that its Board of Directors will convene on 31 August 2026 to consider and approve the interim results for the six months ended 30 June 2026. The agenda also includes deliberation on the declaration of an interim dividend and other routine business matters.

The notice, dated 3 August 2026, was signed by Executive Director and Chairperson Lin Lin. As of the announcement date, the Board comprises three executive directors—Dr. Yu Rong, Ms. Lin Lin, and Ms. Jiang Jing—one non-executive director, Ms. Guo Meiling, and three independent non-executive directors, Dr. Zhang Ying, Mr. Jia Qingfeng, and Dr. Xie Dan.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited have stated they bear no responsibility for the contents of the announcement and disclaim any liability arising from reliance on it.